Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2023, Vol. 28 ›› Issue (4): 463-467.doi: 10.12092/j.issn.1009-2501.2023.04.014

Previous Articles     Next Articles

Controversies over the targets of controlling blood pressure in hyper- tensive patients with chronic kidney disease

NING Sisi1, ZHAO Yuhong1, YAN Lei1, TANG Minna2, ZHANG Ningzhi3, ZHANG Yongqiao3, CUI Zhaoqiang3   

  1. 1Department of internal medicine, Tianshan Hospital of traditional Chinese medicine, Changning District, Shanghai 200051, China; 2Department of Cardiology, Sixth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai 200233, China; 3Shanghai Institute of Cardiovascular Disease-Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China

  • Received:2023-01-17 Revised:2023-03-22 Online:2023-04-26 Published:2023-05-17

Abstract:

The increasing incidence of chronic kid- ney disease (CKD) has become a major global public health problem. Hypertension and CKD can  cause and effect each other and often coexist. Controlling blood pressure is one of the core tasks in the treatment of CKD. Over the past 10 years, many large clinical studies have provided evidence-based medical evidence for the updating and revision of hypertension management guidelines, but there remains controversies in targets of blood pressure in hypertensive patients with CKD. Person- alized and evidence-based management is the key to achieve effective control of blood pressure and slow the progression of CKD. This review will summary the epidemiological status of hypertensive patients with CKD and the progress related to the targets of controlling blood pressure in CKD. 

Key words: hypertension, chronic kidney disease, antihypertensive target

CLC Number: